Novartis to Buy Mariana Oncology for Up to $1.75 Billion in Boost to Radioligand Therapy Business
By Mauro Orru
Novartis agreed to acquire U.S. biotechnology company Mariana Oncology for up to $1.75 billion, in a deal that bolsters its radioligand therapy pipeline and efforts to develop cancer treatments.
The Swiss pharmaceutical company said Thursday that it would pay $1 billion up front for Watertown, Mass.-based Mariana Oncology, with an additional $750 million in payments upon completion of certain milestones.
Mariana Oncology focuses on novel radioligand therapies, or RLTs, to treat cancers. RLTs bind to specific receptors on the surface of certain types of tumors. Once bound, emissions from therapeutic radioisotopes cause DNA damage that can inhibit cell growth and replication.
Novartis currently has two approved RLTs for patients with metastatic castration-resistant prostate cancer and certain types of gastroenteropancreatic neuroendocrine tumors.
The deal is subject to customary closing conditions.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
May 02, 2024 07:36 ET (11:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk